Videos

Hope Rugo, MD, discusses the phase Ib KEYNOTE-028 trial and the impact of its results thus far, as well as the design, findings, and next steps for the trial.

The US Preventive Services Task Force has issued final guidelines that stand by its recommendation that women at average risk of breast cancer should not start routine screenings until they reach age 50 years and that they should then undergo testing every 2 years.

Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, shares the future of surgical treatments for patients with breast cancer.

The FDA has approved a non-alcohol formulation of docetaxel as a treatment for patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

Grade 3 diarrhea occurred in 16% of patients treated with neratinib and prophylactic loperamide, representing a significant reduction compared with phase III findings from the ExteNET trial.

Safety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.

Neoadjuvant chemotherapy for women diagnosed with breast cancer can help shrink a tumor prior to surgery, which can make the procedure minimally invasive and potentially influence prognosis.

Gargi D. Basu, PhD, senior director of Clinical Curation, Ashion Analytics, discusses a study that examined alterations in the cell cycle checkpoint pathway in patients with breast cancer.

Palbociclib enhances cell cycle control when added to anastrazole in the neoadjuvant setting in women with ER-positive primary breast cancer.

The Dignitana DigniCap Cooling System, a computer-controlled device aimed to reduce the severity and frequency of hair loss in patients who receive neoadjuvant or adjuvant chemotherapy for breast cancer, has been cleared by the FDA as the first cooling cap for use in the United States.

The PD-1 inhibitor pembrolizumab had an overall response rate of 12% in PD-L1–positive patients with ER-positive/HER2-negative advanced breast cancer.

The oral pan-HER TKI neratinib continued to show similar rates of disease-free survival for patients with HER2-positive early-stage breast cancer at a 3-year analysis of the phase III ExteNET trial.

Patricia Ganz, MD, UCLA Jonsson Comprehensive Cancer Center, discusses a study comparing anastrozole versus tamoxifen in patients with ductal carcinoma in situ (DCIS) breast cancer.

Joanne Blum, MD, PhD, oncologist with Texas Oncology and a member of the Breast Cancer Committee for The US Oncology Network, discuses the EMBRACA trial.

Treatment with the PI3K inhibitor buparlisib plus fulvestrant showed a 1.9-month extension in progression-free survival compared with fulvestrant alone in women with endocrine-resistant HR-positive/HER2-negative advanced breast cancer.

The enzyme APOBEC3B has been associated with resistance to treatment with tamoxifen in retrospective studies and xenograft models of ER-positive breast cancer.

Estrogen receptor mutations are prevalent and associated with poorer survival in patients with pretreated HR+/HER2- metastatic breast cancer.

Achieving a pCR with standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab was associated with a survival improvement in patients with triple-negative breast cancer.

The risk of complications from mastectomy plus reconstruction was increased by two-fold compared with lumpectomy plus whole breast irradiation, after adjustment for other treatment differences.

Reuben S. Harris, PhD, investigator Howard Hughes Medical Institute and professor in the Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota College of Biological Sciences, explains the role APOBEC3B may play in tamoxifen resistance in ER-positive breast cancer.

Frontline treatment with the PD-L1 inhibitor atezolizumab combined with nab-paclitaxel showed a confirmed objective response rate of 66.7% in patients with metastatic triple-negative breast cancer.

Adding carboplatin to neoadjuvant chemotherapy improves disease-free survival significantly in women with triple-negative breast cancer but not HER2-positive breast cancer.

The FDA has granted a priority review to a supplemental new drug application for palbociclib (Ibrance) for use in combination with fulvestrant in pretreated patients with HR-positive, HER2-negative metastatic breast cancer.

Pat Whitworth, MD, medical oncologist at the Nashville Breast Center, discusses the prospective neo-adjuvant NBRST study, which looked at BluePrint functional subtyping versus conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in breast tumors.

Prophylactic administration of standard heart failure medications helped preserve left ventricular ejection fraction in patients treated with trastuzumab for HER2-positive metastatic breast cancer.

Matthew Goetz, MD, medical oncologist, professor of Oncology, associate professor of Pharmacology, andprofessor of Pharmacology at Mayo Clinic, discusses a phase III study looking at capecitabine (Xeloda) in patients with residual breast cancer following neoadjuvant chemotherapy and surgery.

Treatment with the PD-L1 inhibitor avelumab demonstrated promising overall response rates for patients with PD-L1–positive metastatic breast cancer, particularly for those with triple-negative disease.

Premenopausal women with high-risk breast cancer of the luminal A subtype derive no benefit from adjuvant chemotherapy.

A follow-up analysis of the benefits of adding denosumab to aromatase inhibitor therapy has found that the agent not only helps to prevent fractures, it reduces the risk of recurrence and death in postmenopausal women with HR-positive breast cancer.